14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
TAK vs HLN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
TAK Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)
TAK Overall Winner
6-Pillar Tally: TAK 4 – 1 HLN (1 Tie)
Matrix Metrics: TAK 6 – 4 HLN
As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Haleon plc (HLN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas HLN carries 44.6/100 (HOLD) at $9.21 (15.2x Forward P/E, 23.5% operating margin).
Technical & Structure Timing Caution: TAK trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 73.1); meanwhile HLN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TAK vs HLN. Trailing 12-month operating profitability (TAK 16.6% vs HLN 23.5%) and valuation multiples (TAK 12.7x vs HLN 15.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $67.5B market capitalization and 16.6% operating margin.
OpEx & R&D Reinvestment48.2% of Rev ($12.4B)
90D Engineering Disclosures0 Published
HLN Moat ProfileScale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $40.3B market capitalization and 23.5% operating margin.
OpEx & R&D Reinvestment42.1% of Rev ($4.69B)
90D Engineering Disclosures0 Published
Investor FAQ TAK vs HLN Key Questions & Quantitative Answers
As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Haleon plc (HLN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas HLN carries 44.6/100 (HOLD) at $9.21 (15.2x Forward P/E, 23.5% operating margin). Technical & Structure Timing Caution: TAK trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 73.1); meanwhile HLN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
TAK leads the Growth & Scale pillar: TAK posts +6.7% YoY revenue growth and -9.8% YoY earnings growth on $25.7B TTM revenue (64.8% gross margin, 16.6% operating margin), compared with HLN at +2.2% YoY revenue growth and -4.5% YoY earnings growth on $11.2B TTM revenue (65.6% gross margin, 23.5% operating margin). On trailing 12-month operating scale, TAK generates $25.7B in USD-normalized revenue versus $11.2B for HLN. In operating R&D and SG&A reinvestment, TAK deploys 48.2% of Rev ($12.4B) (0 90-day corporate R&D disclosures) versus 42.1% of Rev ($4.69B) (0 disclosures) for HLN.
TAK screens cheaper on headline valuation multiples. TAK trades at 12.7x Forward P/E, N/M Trailing P/E, 0.47x PEG, and 2.6x EV/Revenue (29.1% EBITDA margin), whereas HLN trades at 15.2x Forward P/E, 18.8x Trailing P/E, 2.08x PEG, and 3.6x EV/Revenue (25.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TAK (0.6% ROE) versus HLN (10.1% ROE) capital efficiency.
In options market volatility and institutional positioning, TAK carries 22.4% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 22% Vol realized risk). By comparison, HLN carries 20.3% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 56% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.